Binding of agonists to G-protein-coupled receptors (GPCRs) activates heterotrimeric G proteins and downstream signaling. Agonistbound GPCRs are then phosphorylated by protein kinases and bound by arrestin to trigger desensitization and endocytosis. Arrestin plays another important signaling function. It recruits and regulates activity of an extracellular signal-regulated kinase (ERK) cascade. However, molecular details and timing of ERK activation remain fundamental unanswered questions that limit understanding of how arrestin-dependent GPCR signaling controls cell functions.
Binding of agonists to G-protein-coupled receptors (GPCRs) activates heterotrimeric G proteins and downstream signaling. Agonistbound GPCRs are then phosphorylated by protein kinases and bound by arrestin to trigger desensitization and endocytosis. Arrestin plays another important signaling function. It recruits and regulates activity of an extracellular signal-regulated kinase (ERK) cascade. However, molecular details and timing of ERK activation remain fundamental unanswered questions that limit understanding of how arrestin-dependent GPCR signaling controls cell functions.
Here we validate and model a system that tracks the dynamics of interactions of arrestin with receptors and of ERK activation using optical reporters. Our intermolecular FRET measurements in living cells are consistent with β-arrestin binding to M 1 muscarinic acetylcholine receptors (M 1 Rs) in two different binding modes, transient and stable. The stable mode persists for minutes after agonist removal. The choice of mode is governed by phosphorylation on key residues in the third intracellular loop of the receptor. We detect a similar intramolecular conformational change in arrestin in either binding mode. It develops within seconds of arrestin binding to the M 1 receptor, and it reverses within seconds of arrestin unbinding from the transient binding mode. Furthermore, we observed that, when stably bound to phosphorylated M 1 R, β-arrestin scaffolds and activates MEK-dependent ERK. In contrast, when transiently bound, β-arrestin reduces ERK activity via recruitment of a protein phosphatase. All this ERK signaling develops at the plasma membrane. In this scaffolding hypothesis, a shifting balance between the two arrestin binding modes determines the degree of ERK activation at the membrane.
arrestin | GPCR | ERK | muscarinic receptor | receptor kinase A rrestin plays a fundamental role in the negative regulation of G-protein-coupled receptors (GPCRs) signaling because its binding to GPCRs hinders G-protein association with the receptors (1) (2) (3) (4) (5) . Arrestin further recruits adaptor proteins and clathrin for the internalization and desensitization of the receptor (6) . Additional functions have been suggested, with β-arrestin producing its own signaling through interactions with other effectors (7) (8) (9) . For example, β-arrestin has binding sites for cRaf (MAPK kinase kinase), MEK (MAPK kinase), and ERK (MAPK) that mediate a signaling cascade for cell proliferation, cell migration, and actin dynamics after GPCR activation (10) (11) (12) (13) . Conventionally, MEK-dependent ERK signaling is described as involving GPCR-arrestin complexes on intracellular compartments such as endosomal vesicles (10, (14) (15) (16) . However, whether similar complexes at the plasma membrane might trigger ERK signaling remains unknown. Electron microscope images of arrestin-receptor complexes together with modeling suggest that β-arrestin binds in two different modes, called transient binding and stable binding, to chimeric β 2 adrenergic receptors (β 2 -AR) containing the C terminus of vasopressin type 2 receptors (3). X-ray crystal structures of rhodopsin-arrestin complexes also support such a concept (4) .
From these observations, a common inference is that ERK activity is up-regulated while scaffolded on arrestin-GPCR complexes.
An interesting alternative mechanism has been suggested recently, namely a briefly persistent conformational change of arrestin that allows it to continue to signal to ERK after dissociation from GPCRs (17)-a "memory effect" (16, 18) . We studied the M 1 muscarinic acetylcholine receptor (M 1 R), which couples to both G q -and arrestin-dependent pathways, including ERK activation (19) (20) (21) (22) , and found strong evidence for two binding modes of arrestin to receptors that led to contrasting downstream signals. The M 1 R is a receptor for which desensitization and internalization are relatively weaker than for, for example, the β 2 -adrenergic receptor. Molecular interactions and conformational changes of arrestin upon M 1 R activation were monitored with intermolecular and intramolecular FRET and total internal reflection fluorescence microscopy. To isolate the arrestin effect on ERK activity, we used arrestin-biased mutations of the receptor.
Results
FRET Reveals Agonist-Induced Interactions of SNAP-Tagged M 1 R with G q and β-Arrestin 2. The formation of complexes between receptors and G proteins or β-arrestin was visualized by constructing fluorescent probes. The intracellular C terminus of the M 1 R was tagged with a SNAP tag (M 1 R-SNAP) (Fig. 1A) . Because the SNAP tag can be labeled with different dyes, the same construct could be used in different spectral combinations in FRET and total internal reflection fluorescence (TIRF) imaging experiments.
As a control, we tested whether the construct had normal function. tsA201 cells transiently expressing M 1 R-SNAP were treated with a cell-permeable SNAP505 dye, and the FRET interactions between G q -CFP and M 1 R-SNAP505 ( Fig. 1 A and B) or between β-arrestin 2-CFP and M 1 R-SNAP505 ( Fig. 1 C and D) were monitored and expressed as FRET ratios (FRETr). Receptor-induced increases Significance G-protein-coupled receptors (GPCRs) can transmit external signals into the cytoplasm via the activation of G proteins. They also mediate G-protein-independent signaling that uses arrestin to activate an extracellular signal-regulated kinase (ERK) cascade. Using real-time optical measurements, we show that arrestin binds in two modes. Stable binding of arrestin to phosphorylated amino acids in the third intracellular loop of the muscarinic receptor upregulates ERK. Transient binding of arrestin to the unphosphorylated receptor downregulates ERK. Thus, the signaling bias of ERK can be determined by binding modes of arrestin to the receptors. Our results suggest a molecular mechanism for GPCR-arrestin-ERK coupling and pave the way for the development of new therapeutic approaches.
of FRETr using the muscarinic agonist oxotremorine (Oxo)-M (1 μM) verified the expected molecular interactions of G q with M 1 R (Fig. 1B) and of β-arrestin 2 with M 1 R (Fig. 1D ). In addition, benzyl quinolone carboxylic acid (BQCA), a specific allosteric modulator of M 1 R, further potentiated the coupling of G q (Fig. 1B) and β-arrestin 2 ( Fig. 1D) to the receptor as previously demonstrated (23) . A competitive M 1 R antagonist, telenzepine (10 μM), almost completely abrogated the ability of a high concentration of oxotremorine (100 μM) to induce a FRETr increase (Fig. 1E , Left and Right), and there was no FRETr response when CFP was used to tag a nonspecific plasma-membrane-anchored LDR construct (5) instead of β-arrestin 2 (Fig. 1F , Left and Right). Thus, the FRETr signals reflect specific binding of G q and β-arrestin 2 to the ligand-bound M 1 receptor.
Distinguishing Transient and Stable Binding Modes of β-Arrestin 2 to
WT M 1 R. Two different modes of binding of arrestin to GPCRs have been suggested from structural studies with chimeric β 2 -AR (3) and rhodopsin (4) . We also could distinguish two modes in our optical experiments in live cells ( Fig. 2A) . We monitored the binding of arrestin to the M 1 R using real-time FRET and TIRF microscopy at high sensitivity in live cells. Application of oxotremorine increased the FRETr interaction between arrestin and M 1 R within a second (Fig. 2B , τ on = 1.2 ± 0.2 s). Following a short (20 s) agonist application, the arrestin-M 1 R FRETr increase was reversed within a few seconds (Fig. 2B , τ off = 4.3 ± 0.8 s) upon washout. In contrast, after an 8-min treatment, only about 67% of the FRETr increase reversed quickly and 33% persisted at least 6 min more after removal of the agonist (labeled "S" component in Fig. 2B ). We denote this persistent component as reflecting a long-lasting "stable binding mode (S)" of the β-arrestin 2/M 1 R complex and the other, quickly reversed portion (∼67%), as reflecting a "transient binding mode (T)." Gaussian fitting to the all-points histogram of FRETr (Fig. 2C ) indicated that the intermolecular FRETr level for the stable binding mode was significantly different from and intermediate between that in the basal state and the total binding seen while agonist was still present. Although the transition from transient to stable binding developed during the 8 min of receptor activation, there was no indication of an additional concomitant intermolecular FRETr change developing during that time. Apparently, the transient and stable complexes have strong and similar FRETr interactions. More conservatively, we could say that the product of the number of arrestin-bound receptors and the FRETr response from each does not change. One possibility is that, within the spatial resolution of FRET interactions (3-8 nm), there may have been no change in distance between the receptor and β-arrestin 2 labels during the switch from transient to stable binding. Increased recruitment and colocalization of β-arrestin with the M 1 R during agonist application could also be seen by TIRF microscopy (Fig. 2D ).
Conformational Change of β-Arrestin 2. Next, we monitored conformational changes of β-arrestin itself to explore a possible temporal relationship with the two modes of binding. Recent studies reported dynamic changes in the N and C domains of β-arrestin following activation of adrenergic and peptide receptors using deuterium exchange (3, 24) and interactions of optical probes (17, 25, 26) . To study conformational changes of β-arrestin induced by the M 1 R in living cells, we measured intramolecular FRET between a FlAsH dye at residue 154 in the N domain of the β-arrestin 2 and CFP fused to the C terminus (FlAsH2-β-arrestin 2-CFP), as described (25, 27) . Incorporating the FlAsH peptide sequence (CCPGCC) into β-arrestin 2 did not modify the persistence or magnitude of the stable binding mode to M 1 R (Fig. 2E ). After labeling with FlAsH dye, the FlAsH-β-arrestin 2-CFP construct reported a clear intramolecular FRETr decrease from arrestin upon activation of the receptor (Fig. 2F) . The recorded decrease suggests that the N domain and the C terminus of β-arrestin 2 move apart during binding to M 1 R. The onset kinetics of the conformational change (τ on = 8.9 ± 1.0 s) were not significantly different from those of the β-arrestin-M 1 R intermolecular FRETr (τ on = 5.9 ± 1.2 s, P = 0.095, Fig. 2G ), indicating that β-arrestin changes its local structure quickly upon binding to the M 1 R. Was the conformational change of β-arrestin maintained even after dissociation from the GPCR? We followed the reversal of the arrestin intramolecular FRETr signal after agonist wash off. The recovery kinetics of the conformational signal showed a fast component and then a persistent plateau (Fig. 2F) , closely resembling the fast unbinding and persistent plateau of β-arrestin interaction with the receptor (intermolecular FRETr) (Fig. 2E) . The relative amplitudes of the persistent components were about the same (intramolecular FRETr: 54 ± 8% versus intermolecular FRETr: 45 ± 9%, P = 0.49; denoted by "S" in Fig. 2 E and F) , and there was no clear difference of delay time after removal of agonist (intramolecular FRETr: 6.6 ± 1.4 s versus intermolecular FRETr: 10 ± 1.2 s, P = 0.088; Fig. 2H ). Thus, we attribute the persistent component to arrestin molecules still bound in stable complexes with the receptor and the early fast-recovering component to arrestin molecules dissociating rapidly from transient complexes and losing their conformational change within seconds. This suggested that β-arrestin molecules retained an altered conformation as long as they remained bound to M 1 R and that arrestins released rapidly from transient complexes reverted quickly to their original state.
Contributions of Stable and Transient Binding of β-Arrestin 2 to ERK Activity. β-Arrestin interacts with members of the MAPK protein kinase cascade cRaf, MEK, and ERK (MAPK) (12, 27) . We tested the contribution of β-arrestin-receptor binding modes to the activation by phosphorylation of the final member, ERK. Our hypothesis was that the stable mode of β-arrestin binding to the receptor mediates MEK and ERK activation. Because ERK can also be activated by G-protein-coupled signaling (28), we switched to a biased mutated M 1 R that binds β-arrestin but not G proteins. Arginine 123, implicated in G-protein binding, was mutated to leucine (R123L) in transmembrane segment 3 (22) . We confirmed that the biased R123L M 1 R did not interact with G q or activate phospholipase C (SI Appendix, Fig. S1 ). Interestingly, the stable interaction between β-arrestin and the receptor was facilitated, so even relatively short agonist treatments initiated some formation of stable complexes ( Fig. 3 A and B and SI Appendix, Fig. S2 ). The development of stable binding was approximately five times faster than for WT M 1 R (Fig. 3B) , and the percentage of stabilized arrestin rose to ∼70% by 8 min. This potentiation might be due to a variety of factors that we have not attempted to sort out. For example, stable arrestin binding is considered to require prior binding of a receptor kinase and phosphorylation of the receptor. Because the biased receptor does not interact productively with G proteins, both the receptor kinase-binding steps and the arrestin-binding steps could be facilitated by an absence of competition from G proteins (29) .
What happens to ERK? We measured the kinase activity of ERK functionally with the fluorescent probe ERK KTR that converts phosphorylation into a nucleocytoplasmic shuttling event (30) . The probe contains ERK substrate, the phosphorylation of which turns off a nuclear localization signal and turns on a nuclear export signal. When phosphorylated by active ERK, the probe is exported from the nucleus, so the ratio of cytoplasmic to nuclear fluorescence intensity (I cyt /I Nuc ) reflects ERK activity. We mention two subtleties in the use of the ERK KTR probe as an indicator of active pERK. One is temporal and one is spatial. The probe probably indicates ERK activity with a delay since the route to phosphorylation may be circuitous. One long scenario could involve pERK being imported into the nucleus, where it phosphorylates the probe, which then is exported to the cytoplasm giving the detected signal. The second subtlety is that the extent of phosphorylation of the probe is a dynamic indicator of two activities: the kinase activity of pERK opposed by protein phosphatase activity. It is possible that some signals from the probe might reflect changes in the relevant phosphatases rather than activation and deactivation of pERK. The real-time measurement with ERK KTR allows us to compare the time course of ERK activity with that of the β-arrestin-M 1 R interaction. As had been observed with the EGF receptor and the same probe (30) , with this biased M 1 R, on average agonist induced a net increase of the ERK KTR ratio, significantly above the resting basal level-a "positive effect" (SI Appendix, Fig.  S3A ). With U0126, an inhibitor of MEK, the positive effect was abolished in most cells, on average being replaced by a "negative effect" (SI Appendix, Fig. S3A ), so, as anticipated, the positive effect reflects phosphorylation of ERK by the upstream MAPK kinase MEK to yield active pERK, which in turn phosphorylates the probe.
The time course of the net MEK-mediated positive effect (SI Appendix, Fig. S3A , dashed line) was estimated by subtracting the averaged ERK activity response with the MEK inhibitor from the averaged control response. This time course matched well the kinetics of the stable binding of β-arrestin to the biased M 1 R (Fig. 3C ) but with phosphorylation of the ERK probe lagging behind stable arrestin binding by ∼20 s. An increased ERK activity was sustained even after removal of the muscarinic agonist, suggesting that, as long as β-arrestin is stably bound, it continues to stimulate ERK phosphorylation. This activation of ERK took place without internalization of the biased receptor (SI Appendix, Fig. S4 ), suggesting that both stable binding of β-arrestin to M 1 R and the MEK-dependent ERK phosphorylation take place at the plasma membrane. Intriguingly, the mutations that produced the biased M 1 R not only removed G-protein interaction but also eliminated induction of the N domain to C-terminal intramolecular FRETr decrease in β-arrestin (SI Appendix, Fig. S5 ). Nevertheless, even in the absence of this arrestin conformational signal, ERK still became activated.
The receptor-stimulated probe phosphorylation by ERK was quite heterogeneous among individual cells (SI Appendix, Fig.  S3B ). The biased receptor resulted in a pure increase in some cells, a biphasic decrease and increase in some cells, and a pure decrease in other cells. The negative-tending trajectory, which became more obvious with the MEK inhibitor U0126 (SI Appendix, Fig. S3 A and C), implies a second receptor-stimulated mechanism that dephosphorylates pERK. Mechanisms underlying negative control of ERK signaling by M 1 R were not resolved in early biochemical studies (23, 31) . However, in published coimmunoprecipitation experiments, activation of dopamine receptors recruited to β-arrestin the serine/threonine protein phosphatase PP2A that dephosphorylated Akt and pERK (32, 33) , and, in mass-spectrometry experiments, activation of angiotensin II receptors recruited the protein phosphatases PP2Cα and PP2Cβ (and the MEK kinase MEKK1) to β-arrestin (7). To test for possible involvement of such phosphatases in the negative control of pERK by M 1 R, we first eliminated the positive effect with the MEK inhibitor. Applying the MEK inhibitor did not change the ERK KTR ratio of resting cells (SI Appendix, Fig. S6A ), consistent with the idea that the kinase had not already been recruited at rest. However, when oxotremorine was added to the inhibitor-treated cells, there was a prominent loss of ERK activity that was significantly prevented by calyculin A, a blocker of serine/threonine protein phosphatases (SI Appendix, Fig. S6B ), and was also prevented by knockdown of β-arrestin 1/2 by siRNA (SI Appendix, Fig. S6C ) (5) . Based on these results, we suggest that, in parallel with activation of ERK by phosphorylation, β-arrestin recruits phosphatases for ERK dephosphorylation during M 1 R stimulation-as previously reported with β-arrestin, Akt, and a dopamine receptor.
Regulation of β-Arrestin 2 Binding and ERK Activation by Protein
Kinases. The relation between stable binding of β-arrestin to M 1 R and the activation of ERK was probed further by modifying receptor phosphorylation. In general, β-arrestin binding is promoted by receptor-dependent phosphorylation of GPCRs through G-protein-coupled receptor kinases (GRKs) (34) (35) (36) (37) or other protein kinases (5, 14, 38) . For the M 1 R or M 3 R, both GRKs and casein kinases may participate in receptor phosphorylation (19, 35, 38) . For the biased M 1 R, we first tried a GRK2/3 inhibitor, cmpd101. This inhibitor significantly reduced both the sustained levels of intermolecular FRETr between the biased receptor and β-arrestin 2 (Fig. 3D ) and the ERK activity after washing agonist off (Fig. 3E) . Again, the profiles of intermolecular FRETr and ERK activity looked similar but with ERK activity lagging ∼50 s behind (Fig. 3F) . In contrast, with the WT M 1 R, the GRK2/3 blocker was without effect (SI Appendix, Fig. S7A ), whereas the casein kinase 2 (CK2) blockers, TTP22 (Fig. 3G) and TBB (SI Appendix, Fig. S7B ), completely prevented stable binding of β-arrestin to receptor. Also the activation of ERK was eliminated by the CK2 inhibitors ( Fig. 3H and SI Appendix, Fig. S7C ). Nevertheless, the transient binding mode still persisted, suggesting again that transient binding does not suffice to activate MEK/ERK signaling. With WT M 1 R, the development of stable β-arrestin binding and the development of ERK activity were slower than with biased M 1 R (Fig. 3 H and I) .
Role of Phosphorylation on the Third Intracellular Loop of M 1 R for
Stable β-Arrestin 2 Binding and ERK Activation. Finally, we asked whether phosphorylation of the receptor is needed for stable β-arrestin binding and for ERK activation. For this test, the biased M 1 R was first further mutated at two key target sites of phosphorylation on the third intracellular loop (39), S228 and S273, to nonphosphorylatable alanines (Fig. 4A) . Mutating the biased receptor significantly reduced the stable binding of β-arrestin to the receptor (Fig. 4B) as well as ERK activation (Fig. 4C) . As a negative control, we tested another mutant that had alanines replacing S451 and S457 in the C tail. This C-tail mutant showed normal stable binding of β-arrestin to the biased M 1 R and normal sustained ERK activity (SI Appendix, Fig. S8 ). These results support the concept that receptor phosphorylation controls stable β-arrestin binding and ERK activation (40) and that the two residues S228 and S273 in the intracellular loop are key, but residues S451 or S457 of the C tail are not. Additionally, based on the significant remaining negative effect on ERK activity (Fig. 4C) , we suggest that protein phosphatases can still be recruited to arrestin that is transiently bound to the receptor.
Kinetic Modeling of Arrestin-Dependent ERK Phosphorylation. Our results gave sufficient quantitative kinetic information to develop a mathematical kinetic description to test our conclusions better. Perforce, the model must make specific assumptions and interpretations. Agreements of the model with the data demonstrate the self-consistency of these assumptions, but do not prove that some other assumptions would not have been consistent as well. We tried not to make unnecessarily complicated assumptions. We first propose a reaction scheme for the biased M 1 R, summarized in Fig. 4D . Starting at the far left in Fig. 4D is the resting inactive, unphosphorylated receptor, and proceeding along the top to the right, it binds ligand, is phosphorylated by GRK, binds arrestin, forms a scaffold for MEK and ERK, and finally ERK is phosphorylated. All these forms have bound ligand. These steps have been described qualitatively before.
After adjustments to fit our observations (see rate constants in SI Appendix, Table S1), our model can generate quantitative predictions for the time courses of each of these sequential steps. We start with an overall view (Fig. 4 E and F) and then proceed to simulations of individual experiments in the subsequent panels of Fig. 4 . Inspection of Fig. 4 E and F suggests three timescales: subsecond, several seconds, and hundreds of seconds. The subsecond kinetics are not well determined as they are below the time resolution of our measurements. Fig. 4E shows that in the model the binding of ligand (k 1 ) is subsecond and that the initial competitive binding of GRK (k 3 ) or arrestin (k 2 ) to RL is very fast, arbitrarily set at 1-2 s. Our live-cell measurements reveal that β-arrestin binds to the M 1 R in multiple kinetically distinguishable modes that have labels such as transient binding, intermediate binding, and stable binding in the diagram. The ligand binding step, the initial transient arrestin binding (Lower row in Fig. 4D ), and the initial GRK binding all reverse in a few seconds when agonist is removed (Fig. 4F) . These steps involve unphosphorylated receptors. Over the few seconds after agonist is applied, GRK phosphorylates receptors, and arrestin slowly begins to be recruited in a more stable complex. For simplicity, we diagrammed the reaction of GRK as two simultaneous phosphorylations forming RLGRKpp. This reaction, followed by loss of GRK and assembly of the arrestin-MEK-ERK scaffold, gradually depletes the initial species RL, RLA, and RLGRK over several hundred seconds, and active ERK (pERK) is formed in this long timescale. The early transient RLA complex recruits a protein phosphatase (PP) (k 12 ) that can dephosphorylate pERK, reducing any tonic background ERK activity. The RLAPP complex is more stable and slower to reverse than RLA. Longer activation of M 1 R leads to MEK-dependent ERK signaling via the stable β-arrestin/phosphorylated-receptor complex. The simulation suggests that the rate-limiting step is recruitment of cRaf/MEK (k 8 ) and that the most stable binding complexes are the cRaf/MEK-, cRaf/MEK/ERK-, and cRaf/MEK/pERK-bound states, ultimately involving ∼76% of the biased receptors. , we assumed that GRK binds to the ligand-bound receptor in a manner competitive with arrestin. The relatively small pool of GRK (0.5 μM) competes with a high concentration of arrestin (15 μM). Formation of the stably bound complex with cRaf and MEK scaffold is >100 times slower than for forming the transiently and intermediately bound states. Therefore, this step, scaffolding cRaf/MEK to the arrestin-receptor complex, is a rate-limiting step for ERK activation. Abbreviations for the different states of the muscarinic receptor (R) are the following: ligand-bound receptor (RL), RL after phosphorylation at the key residues (RLpp), arrestin-bound phosphorylated receptor (RLppA), and RLppA complexed with cRaf/MEK (RLppAM). When ERK binds to RLppAM (RLppAME), MEK phosphorylates ERK (RLppAMpE). The arrestin also binds transiently to RL that lacks phosphorylation at the key residues to form RLA. Then PP produces a small pool of stably bound β-arrestin-M 1 R complex (RLAPP). Our simulation is able to describe time-dependent changes of each state. Change of percentile indicates the portion of the individual states before and after 8 min agonist treatment. The initial transient binding (87%) becomes significantly reduced to 13% after 8 min of agonist treatment because it gradually gives way to the stable binding mode. The final portions of stable binding to phosphorylated and nonphosphorylated receptor were 76% and 5%, respectively; i.e., the majority of stable binding of arrestin occurs with the phosphorylated receptor. (Fig. 3B) . The error bars in the experimental data are SDs. (J-K) Simulated effect of the GRK blocker and mutations at the key phosphorylation sites on arrestin binding to the receptor. (J) The forward rate constant of phosphorylation (k 4 ) was set to zero to mimic the effect of blocking GRK (Fig. 3D) . (K) Mutation of phosphorylation sites changes the binding affinity of GRK to the ligand-bound receptor. The forward rate constant for binding of GRK (k 3 ) was set to zero. The mutations accelerated arrestin binding to the receptor as measured with FRETr (red symbols in B) and as simulated (red line, K). (L) Simulated ERK phosphorylation in control or mutated (S228A/S273A) biased receptor when k 3 equals to zero. **P = 0.01 and *P = 0.03 for B and C, respectively.
The kinetic model in Fig. 4D (Figs. 4 G-I and SI Appendix, Fig. S9 ). Blocking the phosphorylation step (k 4 ) by GRK inhibition removes the stable binding (Fig. 4J) . Setting the rate constant for the GRK-binding step (k 3 ) to zero (Fig. 4K ) mimics the effect of mutating two phosphorylation sites in Fig. 4B , consistent with the hypothesis that the double mutant decreases the binding affinity for GRK in addition to eliminating sites of phosphorylation. With k 3 = 0, there is no stable arrestin binding along the upper pathway so that now the transient-binding lower pathway is augmented. The model also shows binding of protein phosphatase to the transient RLA form to yield RLAPP. Although involving only a small portion of the biased receptors (5%), this complex had to be made stable after the removal of the agonist to prevent the continued rise of the pERK level (Fig. 4L) . The abundance of the RLAPP complex rose to 20% for the phosphorylation mutant (S228A/S273A) where its precursor the transient RLA form was augmented (Fig.  4K ). In addition, our model reliably captures the interplay between positive regulation of ERK activity by the recruitment of MEK (SI Appendix, Fig. S3 D-F) and negative regulation by protein phosphatase (SI Appendix, Fig. S6 D-F) . Taken together, the strength of ERK activity is controlled by a balance between the transient and stable branches of arrestin binding to M 1 R (Lower and Upper rows in Fig. 4D, respectively) .
The kinetics of WT M 1 R were modeled in the same manner (Fig. 5A ). However, GRK was replaced by CK2 as suggested by our experiments (Fig. 3 G-I) and by previous literature. GRK has a PIP 2 -binding pleckstrin homology domain that helps to anchor it at the plasma membrane (41) . However, because the WT M 1 R couples to G q , when the receptor is activated, PIP 2 becomes depleted by phospholipase C (PLC), allowing the membrane pool of GRK to drift away. Thus, GRK becomes less available during strong activity of G q -coupled receptors. Instead, cytosolic casein kinases phosphorylate WT M 1 R, albeit more slowly than GRK phosphorylates the biased receptor. Therefore, quite different kinetics and steady-state levels of stable arrestin binding (Fig. 3B ) result for WT versus biased receptors (Fig. 5 B and C) . Our WT M 1 R model described well the observed real-time FRET between receptor and arrestin (Fig. 5D) , the time course of stabilization of arrestin depending on the duration of agonist application (Fig. 5 E  and F, solid circles) , and the delayed increase of pERK after significant dephosphorylation of pERK by protein phosphatase (Fig. 5F, line) . The WT model did not reproduce the continued phosphorylation of ERK after washing off the agonist. Presumably, the amount of pERK is regulated by other G-proteindependent mechanisms as described previously (27) .
Discussion
We have described the real-time kinetics of arrestin binding to the M 1 R followed by scaffolding of the MAPK pathway, and we have encapsulated them as a kinetic model. In some proposals for other GPCRs, β-arrestin first couples loosely to phosphorylated residues in the C terminus of an activated receptor and then more tightly to the core region of the receptor via the finger loop region of arrestin (3, 4) . However, unlike rhodopsin and the β 2 -AR, M 1 R has only three potential phosphorylation sites in the C terminus, and, as we saw, mutating two of the serines there does not abrogate β-arrestin binding. Additionally, in a recent M 1 R crystal structure, the C-terminal tail seems poorly aligned to make an interface to β-arrestin 1 (42) . Based on molecular modeling that compares the M 1 R C tail with that of PAR2 [SI Appendix, Fig. S10 A and B; see Materials and Methods for details of Iterative Threading Assembly Refinement (I-TASSER) modeling], we speculate that the third intracellular loop of M 1 R (missing in the crystal structure) crowds the C terminus. However, that loop apparently forms the interface region for arrestin binding and contains 12 serine/threonine residues. We have established two of these residues as key for phosphorylation, and their mutation weakens the stable binding of β-arrestin considerably. We postulate that arrestin binds (Upper Right in Figs. 4D and 5A) to phosphorylated sites in the third intracellular loop of M 1 R and then interacts with effector proteins such as cRaf, MEK, and ERK, further stabilizing the β-arrestin-M 1 R complex. With our optical measurements on the M 1 R, we found that stably bound β-arrestin forms a platform for the activation of the ERK signaling and that, upon subsequent dissociation of this complex, signaling from β-arrestin stops.
Conformational changes of arrestin after activation of the β 2 -AR may be important for signaling to downstream effectors (17, 26) . It has been suggested that, like G proteins, arrestin might be able to dissociate from active β 1 -AR while still retaining an activated signaling conformation, a "memory effect" (16, 18) . From our observations with the M 1 R, we can say that the recorded arrestin conformational change in the unliganded transient complex with receptor reverses very quickly after arrestin unbinds with no memory effect after transient binding. On the other hand, the arrestin conformational change in the activated stable complex is surprisingly long lasting. We attribute this to persistence of the complex itself for >400 s. Because there is little dissociation of the complex in that time, we cannot say whether the arrestin has an additional memory after dissociation from the stable complex with the M 1 R. Our broad supposition is that different receptors induce unique binding modes of arrestin, depending on the shape of the C tail and the size of the third intracellular loop of the active receptor, as well as the number and location of phosphorylation sites. Key factors for recruiting and stabilizing arrestin may be the alignment of the C-terminal tail of the receptor and how much the interface is screened by the third intracellular loop. Such factors are hard to compare among different receptors using a real-time FRET assay, but, according to our I-TASSER modeling, β-ARs have a less bulky third intracellular loop compared with muscarinic receptors. This situation leaves open the possibility that β-ARs may have different binding modes with arrestin that are released sooner and might give rise to memory effects.
So far, we have focused on the roles of specific receptor regions for recruiting arrestins. Unexpectedly, we found that the biased M 1 R without G-protein interaction did not induce an intramolecular FRET change of arrestin but still stimulated the MAPK pathway. At face value, this could mean that an arrestin conformational change is not needed for activation of ERK by the biased M 1 R; however, several other possibilities cannot be excluded. First, there may be a conformational change that is not captured by FRET between residue 154 and the C terminus of arrestin. Second, in line with a mega-complex model of receptor-G protein-arrestin (43), G proteins or their signaling may promote a conformational change of arrestin. This model proposed that the G protein and arrestin could be physically bound to the same receptor so that, for example, the G protein interacts with a core region of the receptor whereas arrestin hangs from the C-terminal tail of the receptor. Third, different GPCR kinases could generate distinct conformations of arrestin when they interact with active receptors.
GRKs are considered the primary kinases for phosphorylation of active rhodopsin and β-adrenergic receptors. One factor that aids receptor-induced plasma-membrane recruitment of GRK2/3 is binding to the G βγ subunits dissociated from heterotrimeric G proteins (41) , and another factor is binding to negatively charged phospholipids including the phosphatidylinositides PIP 2 and PIP (41, 44) . We found that the biased M 1 R, unable to activate G q proteins or to stimulate PLC-dependent hydrolysis of PIP 2 , still appeared to be phosphorylated by GRKs (Fig. 3 D-F) . In this case, basal PIP 2 may suffice to localize GRKs. Although it generates diffusible G βγ , the WT M 1 R is phosphorylated by CK2 instead of GRK2/3 possibly because it substantially reduces plasma membrane PIP 2 and PIP with the strong stimuli that we use (20, 45) .
What is the physiological significance of switching regulation of ERK activity by two modes of β-arrestin binding relying on receptor phosphorylation? We speculate that there is time-and intensity-dependent switching for different signals. For example, a short-term activation of muscarinic receptor at a cholinergic synapse can evoke G q -coupled activation of phospholipase C and subsequent IP 3 -and diacylglycerol-dependent signaling. Evidently, transiently bound β-arrestin may also down-regulate any ongoing ERK signaling by ERK dephosphorylation (SI Appendix, Fig. S9 ). Longer activation of the receptor evokes stable binding of β-arrestin and augments ERK signaling, a molecular mechanism that could be involved in modulation of ion channels (46, 47) and formation of long-term memories (30, 39, 48) . Evidently, by itself β-arrestin 1, but not β-arrestin 2, can act directly on plasma membrane ion channels (49) .
Previous work with angiotensin II, vasopressin, and proteaseactivated receptors has suggested that phosphorylation of ERK follows internalization of complexed receptors via specific targeted endosomal vesicles (10, 14, 15) . In contrast, our study of M 1 R supports the concept that significant MEK/ERK signaling starts at the plasma membrane without internalization of the receptor-β-arrestin complex (50) . ERK activation at the cell surface could be physiologically significant for M 1 R (and β 1 adrenergic receptors) that experience much less internalization compared with β 2 -AR (SI Appendix, Fig. S4 ) (18) . Finally, in good agreement with barcode (51, 52) or multisite phosphorylationthreshold (53) hypotheses of phosphorylation of receptors, the extent and position of receptor phosphorylation by protein kinases controls downstream MEK/ERK signaling via the binding stability of β-arrestin to M 1 R. Altogether, our study provides a molecular explanation for differential signaling from a GPCR because it couples to MEK/ERK signaling and paves the way for the development of new therapeutic approaches.
Materials and Methods
Reagents and Solution. Cell-permeable SNAP505 and SNAP647 dyes were from New England Biolabs. For labeling with SNAP505 dye, cells were incubated with 5 μM dye in a 37°C CO 2 incubator for 75-90 min, and then free dye was washed out three times with cell culture medium. For SNAP647 dye, 2 ) from the activated WT M 1 R is estimated to be ∼100-fold lower than hydrolyzed PIs (PIP 2 and PIP) and much lower than cytosolic arrestin. We did not include possible contributions of G proteins for competing with arrestin at active receptors. Rate constants for some of steps were different from those for the biased receptor (SI Appendix, Table S1 the concentration was 0.3 μM, and the time was 5-10 min. Labeled cells were incubated in culture medium for at least 1 h before measurements were taken. M 1 Rs were cloned into the pSNAP f vector, putting the SNAP tag at the receptor C terminus. FlAsH-EDT2 [4′,5′-bis(1,3,2-dithioarsolan-2-yl) fluorescein-(1,2-ethanedithiol)2] dye and EDT (1, 2-ethanedithiol) were purchased from Santa Cruz Biotechnology. G q -CFP and β-arrestin 2-CFP constructs were provided by Joachim Goedhart, University of Amsterdam, Amsterdam, The Netherlands, and Moritz Bünemann, University of Würz-burg, Würzburg, Germany, respectively. The β-arrestin 2-CFP FlAsH2 construct, obtained from Carsten Hoffman, University of Würzburg, Würzburg, Germany, had the FlAsH peptide sequence (CCPGCC) between residues 154 and 155 in the N domain of β-arrestin (17) . An EDT solution was used before FlAsH labeling with EDT2 dye to reduce nonspecific labeling of offtarget proteins. First, 1 M EDT in dimethyl sulfoxide (DMSO) was prepared from the 9.5-M stock bottle (Santa Cruz Biotechnology) in the fume hood and diluted to 250 μM and further diluted to 10 μM in normal Ringer's solution (see below). Cells were preincubated with 10 μM EDT and then treated with 0.5 μM FlAsH-EDT2 in the presence of 10 μM EDT for ∼90 min in the 37°C CO 2 incubator. The dye was washed out with Ringer's solution containing 250 μM EDT for 5 min, and the cells were placed in the incubator for at least 1 h before the experiments. The ERK KTR vector (pLentiCMV Puro DEST ERKKTRClover), originally made by the Covert laboratory (29) , was obtained from Addgene (#59150). TTP 22 and TBB were purchased from Tocris, and cmpd101 (GRK2/3 blocker) was from HelloBio. Oxo was from Sigma-Aldrich. The cell-permeable SNAP-cell star 505 (1 mM, SNAP505), SNAP-cell 647 (0.6 mM, SNAP647), and FlAsH-EDT2 (1 mM) were dissolved in DMSO. Oxotremorine was made as 10 mM of stock with distilled water. Stock solutions for TTP22 (100 mM), TBB (100 mM), calyculin A (20 μM), and cmpd101 (30 mM) were prepared in DMSO. Vigene Biosciences produced all mutants of the SNAP-tagged M 1 R using our WT M 1 R in pSNAPf vector. Standard external Ringer's solution contained (in mM): 137.5 NaCl, 2.5 KCl, 2 CaCl 2 , 1 MgCl 2 , 10 glucose, and 10 Hepes (pH adjusted to 7.3 with NaOH). All experimental recordings were made at room temperature (22-24°C).
Cell Culture and Transfection. Human embryonic kidney 293-derived tsA201 cells were obtained from Sigma-Aldrich. The cells were cultured in DMEM containing glutamine (2 mM), sodium pyruvate, and glucose (25 mM) supplemented with 10% FBS, 1% penicillin, and streptomycin and subcultured every 3-4 d using 0.05% trypsin and EDTA. Cells were transfected with different amounts of cDNA depending on the type of experiment. For normal FRET experiments, we used 1 μg of cDNA for β-arrestins, G-protein subunits, and receptors. For FRET measurements between G q and M 1 R, we transfected with equal amounts of G q -CFP, G β1 , and G γ2 , as well as M 1 R-SNAP constructs without β-arrestin constructs (20) . For FRET between β-arrestin and M 1 R, cells were transfected with β-arrestins and M 1 R-SNAP without cDNA of G proteins. For confocal experiments, we used 0.3 μg cDNA for red fluorescent protein (RFP)-tagged PI(4,5)P 2 sensitive pleckstrin homology domain probe (PH-RFP) and 1 μg cDNA for receptors. For TIRF experiments at high sensitivity, we used ∼20-fold less cDNA for receptors (TIRF Microscopy). X-tremegene 9 DNA transfection reagent (10 μL, Roche Applied Science) and cDNA were added to Opti-MEM solution (∼87 μL) sequentially. Cells at ∼75% confluency in a 35-mm culture dish were washed with Opti-MEM and supplemented with 0.5 mL Opti-MEM solution. Then the mixture of the transfection reagent and cDNAs (∼100 μL) was added into the Opti-MEM. Cells were incubated for 4-6 h. Finally, cells were treated with trypsin (0.05%, Sigma-Aldrich) and seeded onto small 5-mm glass chips for confocal and FRET experiments or 25-mm round coverslips for TIRF imaging. The glass chips and coverslips were coated with poly-L-ornithine (1 mg/mL, Sigma-Aldrich).
FRET. The measurements were performed as described previously (5, 20) . Briefly, epifluorescence photometry was used to measure the FRET between CFP and SNAP505 dye or between CFP and FlAsH dye. Emission light from CFP and SNAP505 (or FlAsH) was collected by photomultipliers in photoncounting mode using an inverted Nikon Diaphot microscope equipped with a 40× 1.3 N.A. oil-immersion objective. CFP was excited at 440 nm, and emissions for CFP and SNAP505 (or FlAsH) were collected at 480 nm and 535 nm, respectively. FRETr was taken as the ratio of SNAP505 (or FlAsH) emission divided by CFP emission after correction for background and bleedthrough. FRETr values were normalized to the control value before treatment with agonist to remove cell-to-cell variation. We collected data points every 1 s and used a local perfusion system that can exchange solutions within 1 s.
TIRF Microscopy. For dual-color imaging in Fig. 2D , cells expressed SNAPtagged WT M 1 R and β-arrestin 2 YFP. To label the SNAP tag, the cells were incubated with 0.3 μM SNAP647 dye for 5-10 min in the culture medium at 37°C and then washed three times. The washing step is critical to remove the remaining dye from the cell interior. Cells were further incubated for at least 1 h before imaging. Photobleaching of the SNAP647 dye on the receptor was ∼15% within 1.5 s with a sampling rate of 33 frames/s. In the TIRF experiments, nonbleached receptors reentered the evanescent field from other regions of the cells during the intervals before and after treatment with agonist. To improve detection of YFP-tagged arrestin at near single-molecule sensitivity, we optimized several parameters: (i) to reduce the background signal, cDNA for arrestin (0.05 μg) was 20-fold less than used for ensemble FRET experiments (1 μg); (ii) to minimize the background signal collected from the cytosol, the angle of the TIRF excitation lasers was carefully adjusted in our home-built TIRF microscope (5); (iii) to reduce photobleaching of YFP-tagged arrestin, the power of the excitation laser was reduced, and the sampling time was kept at 30 ms to collect sufficient photons; and (iv) the high-gain mode was selected in the EMCCD camera (Andor). The cytosolic fluorescence was far brighter than that from the plasma membrane in epifluorescence mode, in agreement with previous observations that most arrestins are located in the cytosol. Most of the background signal bleached quickly after exposure to the laser light (5) . TIRF images at high sensitivity were taken on a Nikon Eclipse Ti microscope with an APO TIRF 100×/1.49 N.A. objective (5) . Separate lasers at 488 nm and 641 nm were used for the excitation of YFP and SNAP647 dye, respectively. Images were collected by the EMCCD cameras and a custom-built controller written in LabVIEW as described. Separate EMCCDs were used for simultaneously collecting emission from YFP and SNAP dye. Multifluorescence solid latex beads (0.5 μm, Polysciences) were used to correct position differences in the two EMCCD cameras in Image J (NIH). The images showed bright spots (puncta) of arrestin and receptor (Fig. 2D) . The puncta were not further analyzed to determine whether they represented single molecules or small clusters of molecules.
Real-Time Imaging of ERK Activity. The ERK KTR probe was used to measure phosphorylated ERK activity (30) . The tsA201 cells were transiently transfected with the probe and M 1 R 1 d before use. The probe was excited at 488 nm using a Polychrome IV monochromator (Till Photonics), and the emission signal was recorded at 510 nm every 4 s using an EMCCD camera (Photometrics Technology) in an inverted Nikon TE2000 microscope equipped with a 20× objective lens and additional 1.5× magnification. For analysis, nuclear and the cytoplasmic regions-of-interest were identified from pseudocolor images. Background fluorescence measured in a cellfree area was subtracted.
Confocal Microscopy. Confocal images were taken every 12 s for the PH-RFP probe to monitor PIP 2 depletion by SNAP-tagged M 1 R with a Zeiss 710 confocal microscope (SI Appendix, Fig. S1C ). Excitation and emission light were delivered and collected by a 40× oil immersion lens (1.3 N.A.) as previously (5).
Mathematical Modeling. M 1 R-and β-arrestin-mediated cell signaling was simulated using a rule-based, deterministic, compartmental model in Virtual Cell version 6 (University of Connecticut). Reactions were represented as first-order chemical kinetic equations without any spatial diffusion of molecules. The kinetic model defines molecule pools by the states and reactions described in Figs. 4D and 5A with rate constants and initial conditions given in SI Appendix, Table S1 . The numerical parameters were based on literature values where possible and adjusted manually for description of our data.
GPCR Structure Predicted with I-TASSER. The I-TASSER server was developed by the Y. Zhang laboratory (University of Michigan). The structure of G-proteincoupled M 1 R and PAR2 were predicted using their server. The protocol for I-TASSER is detailed in their publication (54) . In principle, I-TASSER predicts the structure of proteins of interest using an iterative threading assembly refinement. The predicted structure matches the 3D models with other known proteins and then finds the lowest energy level for the final structure. It has different features compared with homology modeling, which considers only similarity of the query structure with the known template structure. If similar structures are publically available, homology modeling would be more accurate.
If not, the I-TASSER approaches can solve unknown domain or whole structures. For example, the crystal structure of the seven transmembrane domains of M 1 R was fully resolved (41) , but the C tail and third intracellular loop of the receptor were not due to flexibility and truncation for insertion of a reference protein (T4 lysozyme), respectively. Therefore, in this study, we used I-TASSER modeling to complete the structure of M 1 R. The PAR1 and a new PAR2 structure are also available, but the C terminus tail and ICL3 regions are not included (55, 56) . With I-TASSER, the c-score indicates the accuracy of the predictions and 90% accuracy of the protein fold is expected for a c-score > −1.5. The c-scores in our simulation were −1.59 and −0.77 for mouse M 1 R and human PAR2, respectively. Another important parameter is the TM score (0-1), which provides topological information. TM > 0.5 means a correct topology, and a TM score <0.17 suggests a random structure. TM scores were 0.51 and 0.62 for M 1 R and PAR2, respectively. The simulated results were rendered in PyMOL.
Statistics. All statistical tests are performed using Student's t test with Excel software (Microsoft), and we report average ± SEM in the main text and figure legends. P < 0.05 was considered statistically significant. N and n indicate independent experiments and the total number of single cells, respectively. Fig. 4D ). For the blue lines, MEK activity was reduced stepwise by 10%. For the red lines, the phosphatase activity was reduced stepwise by 10%. The black line in the middle represents 100% activity for each and is identical to Control in D. ( F) Simulations obtained by varying the rate constant for MEK (0 to 9% of maximum rate constant) at a fixed rate constant for protein phosphatase (100%). 100 µM Oxo was used for all experiments and simulations. Fig. 4D) . (E) To simulate the effect of calyculin A, the protein phosphatase was reduced to 10% by adjusting the rate constant of Reaction 13 in Fig.  4D . (F) For knock-down of β-arrestin 1/2 using siRNA, 96.5% of arrestin was assumed to be removed ('3.5% β-arr1/2'). 100 µM Oxo was used in all experiments and simulations. S10 . Simulation of mouse M1R and human PAR2 structures. The whole structures of M1R (A) and PAR2 (B) were simulated with I-TASSER. The C-tail of each receptor is highlighted in red. The C-tail of M1R extending from helix 8 (H8) was not well positioned to the cytosolic interface to interact with arrestin partly because of occlusion by the extensive intracellular loop, while that of PAR2 is well exposed for arrestin binding. See Materials and Methods for detailed description about this simulation. 
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